The Board of Indivior PLC announced the appointment of David E. Wheadon, M.D. as an Independent Non-Executive Director of the Company with effect from June 1, 2024. Dr. Wheadon is a health policy leader and physician with more than three decades of global experience in the pharmaceutical industry. Dr. Wheadon previously served as senior vice president of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019.

Prior to that, he was executive vice president, research and advocacy at Juvenile Diabetes Research Foundation International Inc., from May 2013 to December 2014, and senior vice president, scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), from January 2009 to May 2013. Dr. Wheadon served as vice president, global pharmaceutical regulatory and medical science, and group vice president, global pharmaceutical regulatory affairs at Abbott Laboratories from 2005 to 2009. Prior to Abbott Laboratories, Dr. Wheadon held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company.

Dr. Wheadon received his M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts. Dr. Wheadon is a Non-executive Independent Director of Sotera Health Company (Nasdaq: SHC), Vaxart Inc. (Nasdaq: VXRT), and ConnectiveRx.

He also serves as a member of the Board of Trustees of Mount Sinai Health System. Prior to its recent acquisition by Bristol-Myers Squibb Company, Dr. Wheadon served as a Non-executive Independent Director of Karuna Therapeutics Inc.